Roche (ROG) Given a CHF 300 Price Target at JPMorgan Chase
A number of other research analysts have also recently commented on ROG. Barclays set a CHF 305 price target on shares of Roche and gave the stock a buy rating in a report on Thursday, December 21st. Nord/LB restated a buy rating on shares of Roche in a report on Wednesday, December 27th. Jefferies Group set a CHF 300 price target on shares of Roche and gave the stock a buy rating in a report on Friday, January 5th. UBS set a CHF 260 price target on shares of Roche and gave the stock a neutral rating in a report on Monday, January 8th. Finally, Societe Generale set a CHF 190 price target on shares of Roche and gave the stock a sell rating in a report on Monday, January 15th. Five equities research analysts have rated the stock with a sell rating, six have given a hold rating and ten have assigned a buy rating to the stock. The stock has a consensus rating of Hold and an average price target of CHF 253.30.
VTX ROG opened at CHF 219.60 on Friday. Roche has a 12 month low of CHF 214.30 and a 12 month high of CHF 273.
WARNING: “Roche (ROG) Given a CHF 300 Price Target at JPMorgan Chase” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.dailypolitical.com/2018/04/16/roche-rog-given-a-chf-300-price-target-at-jpmorgan-chase.html.
Rogers Corporation designs, develops, manufactures, and sells engineered materials and components worldwide. The company's Advanced Connectivity Solutions segment offers circuit materials and solutions for connectivity applications in wireless communications infrastructure, automotive, connected devices, wired infrastructure, consumer electronics, and aerospace/defense.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.